AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors

• First-quarter revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease.
• The biotech firm reiterated its FY2026 revenue guidance of $315 million to $325 million.
• Aurinia’s earnings of $0.25 per share topped analysts’ estimates of $0.20 per share.

Shares of Aurinia Pharmaceuticals (AUPH) fell more than 10% on Thursday, marking their steepest single-day drop in over nine months, as investors appeared unsettled by the lack of an earnings call and limited pipeline updates despite the company posting a first-quarter earnings beat.

The report marked Aurinia’s first quarterly update since a sweeping leadership overhaul in March. The company appointed industry veteran Kevin Tang as CEO to replace Peter Greenleaf, who served in the position for seven years. The company also named Michael Hearne as CFO, Ryan Cole as COO, and Thomas Wei as Chief Scientific Officer.

AUPH Sees Revenue Growth Across All Segments

Aurinia reported first-quarter revenue of $77.7 million, up 24% year over year and ahead of Wall Street expectations of about $77 million, according to Fiscal.ai data. The company posted earnings of $0.25 per share, topping analysts’ estimates of $0.20 per share.

Revenue growth was driven by a 23% increase in net sales of Lupkynis, an oral treatment for adults with active lupus nephritis, a serious kidney disease. Meanwhile, revenue from Aurinia’s licensing, collaboration, and royalty agreement with Otsuka rose 64% to $4.1 million.

The biotech firm reiterated its full-year 2026 revenue guidance of $315 million to $325 million, up 11% to 15% year over year.  

Retail Questions Lack Of Information

Despite the sharp intraday fall, retail sentiment for AUPH turned ‘bullish’ from ‘bearish’ a day earlier, while message volumes were ‘high.’

One user questioned the lack of an earnings call and asked why the company did not provide updates on its clinical trials for Aritinercept, an autoimmune disease drug candidate under development for three potential uses. The company had earlier announced plans to begin a clinical study of Aritinercept in the first half of 2026.

Another user remained bullish but said they hoped for more clinical updates and merger information.

The stock has shed around 10% so far this year.

Read also: KALA Stock Hits Record Low – Firm Announces Reverse Split After Shares Fail To Surpass The $1 Mark

For updates and corrections, email newsroom[at]stocktwits[dot]com.